Should I Buy CRMD? CRMD 2026 Analysis

Should You Buy CorMedix Inc (CRMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

8.020

1 Day change

3.48%

52 Week Range

17.430

Analysis Updated At

2026/01/28

Buy (for a beginner long-term investor): CRMD looks attractive at ~$7.77 because Street targets were cut but still imply large upside ($13–$16), options positioning is bullish (low put/call ratios), and the latest reported quarter showed very strong revenue growth. Technically it’s still in a broader bearish trend (moving averages), but momentum is improving (MACD positive). Given you’re impatient and not waiting for an “ideal” entry, this is a reasonable buy now rather than a hold/sell.

Technical Analysis

Price ~$7.765 with slight green regular session (+0.19%) and mild pre-market softness (-0.65%). Trend is still bearish on moving averages (SMA_200 > SMA_20 > SMA_5), which signals the longer-term downtrend hasn’t fully reversed. However, momentum is turning: MACD histogram is positive and expanding (0.0385), suggesting improving upside pressure. RSI(6) ~50 is neutral (no overbought/oversold). Key levels: support near pivot 7.26 (then S1 6.74), resistance is tight overhead at R1 7.784 and R2 8.107—so a clean break above ~7.78–8.11 would confirm better near-term trend strength.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options sentiment skews bullish: put/call ratios are low on both open interest (0.37) and volume (0.33), implying more call interest than puts. Implied volatility is elevated (30D IV ~65%) but IV rank/percentile are relatively low (IV rank ~18, IV percentile ~24), meaning volatility is not extreme vs its own history. Volume is below its 30-day average (~77%), but open interest is slightly elevated vs average (~111%), suggesting positioning is still present even if today’s trading isn’t unusually active.

Technical Summary

Sell

Buy

Positive Catalysts

Potential event catalyst: the company is expected to provide more detail at the Feb 10 Investor Day (per Truist note). Prior commentary highlighted increased diversification after the Melinta acquisition close (noted after the Q3 report). Options market positioning is call-heavy, which often aligns with positive sentiment/expectations.

Neutral/Negative Catalysts

Recent guidance reset: FY26 revenue guidance and 2027 DefenCath revenue outlook came in well below prior Street expectations, driving multiple sharp price-target cuts (RBC $22→$13, Truist $20→$16, H.C. Wainwright $18→$13). Technical picture remains weak on longer-term trend (bearish moving averages) and the stock is sitting just below near-term resistance (~7.78), which can cap upside until broken. No supportive news flow in the last week to counterbalance the guidance-driven reset.

Financial Performance

Latest quarter (2025/Q3): Revenue rose to 104,275,289 (+810.22% YoY), showing a sharp acceleration in top-line performance. However, profitability metrics weakened materially YoY: Net income fell to 108,562,980 (-4009.63% YoY) and EPS to 1.26 (-2620.00% YoY), while gross margin declined to 89.26% (-5.05% YoY). Net takeaway: strong growth on revenue, but earnings comparability and sustainability look less clear based on the reported YoY drops in net income/EPS.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend is negative on targets but ratings remain positive: In Jan 2026, RBC cut PT from $22 to $13 (kept Outperform), Truist cut PT $20 to $16 (kept Buy), and H.C. Wainwright cut PT $18 to $13 (kept Buy). The message from Wall Street: pros—still meaningful upside vs current price and belief in the story if execution holds; cons—expectations have been reset due to weaker 2026–2027 DefenCath guidance, and the stock’s next phase depends more on execution outcomes. Influential/political trading: no recent Congress trading data available; hedge funds and insiders show neutral recent activity.

6 Analyst Rating

Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 17 USD with a low forecast of 14 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.750

Low

Averages

High

Current: 7.750

Low

Averages

High

H.C. Wainwright

Buy

downgrade

$18 -> $13

AI Analysis

2026-01-23

Reason

H.C. Wainwright

Price Target

$18 -> $13

AI Analysis

2026-01-23

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on CorMedix to $13 from $18 and keeps a Buy rating on the shares. The firm says expectations have been reset following the updated 2026-2027 DefenCath guidance. CorMedix has entered the next phase of the story where clinical execution now matters more than commercial execution, the analyst tells investors in a research note.

RBC Capital

Outperform -> NULL

downgrade

$22 -> $13

2026-01-21

Reason

RBC Capital

Price Target

$22 -> $13

2026-01-21

downgrade

Outperform -> NULL

Reason

RBC Capital lowered the firm's price target on CorMedix to $13 from $22 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRMD

Unlock Now

CRMD Should I Buy

CRMD Should I Buy

Should You Buy CorMedix Inc (CRMD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch